Cdk5 (DC 17) Antibody from Santa Cruz Biotechnology, Inc.

Yes, the Cdk5 (DC 17) Antibody has been utilized in studies investigating tau hyperphosphorylation in rat models, particularly in the context of diabetic ketoacidosis, which is linked to Alzheimer's disease. Research has shown that Cdk5 activation is involved in the phosphorylation of tau, contributing to neurodegeneration (basurtoi2024).

The Cdk5 (DC 17) Antibody has been shown to work effectively in Western blotting applications, as evidenced by its use in various studies to detect Cdk5 levels and activity in different experimental setups, including those related to neuronal signaling and plasticity (dimeco2019, hernande2024).

Cdk5 is implicated in the modulation of synaptic plasticity, particularly in the context of neurodegenerative diseases. Studies have demonstrated that inhibition of Cdk5 can affect long-term depression and potentiation in striatal neurons, indicating its critical role in synaptic signaling pathways. The Cdk5 (DC 17) Antibody can be used to investigate these mechanisms further (hernande2024).

Yes, the Cdk5 (DC 17) Antibody has been referenced in studies exploring its role in glioblastoma, where Cdk5 is involved in tumorigenicity through the phosphorylation of substrates like TRIM59. This suggests that the antibody could be useful in cancer research focused on the signaling pathways regulated by Cdk5 (sang2019).